BioAge Labs (BIOA) – Investment Analysts’ Recent Ratings Updates

A number of firms have modified their ratings and price targets on shares of BioAge Labs (NASDAQ: BIOA) recently:

• 10/26/2026 – BioAge Labs was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 10/11/2026 – BioAge Labs is now covered by UBS Group. They set a “neutral” rating and a $8.00 price target on the stock.
• 10/11/2026 – BioAge Labs was upgraded by UBS Group to “hold”.
• 10/10/2026 – BioAge Labs was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 10/8/2026 – BioAge Labs was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 9/13/2026 – BioAge Labs was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 9/9/2026 – BioAge Labs had its “buy” rating reaffirmed by Roth Capital. They now have a $25.00 price target on the stock.
• 9/8/2026 – BioAge Labs had its “buy” rating reaffirmed by BTIG Research. They now have a $40.00 price target on the stock.
• 9/5/2026 – BioAge Labs was downgraded by Wall Street Zen from “sell” to “strong sell”.

BioAge Labs, Inc is a clinical-stage biotechnology company focused on developing medicines that target the biological mechanisms of aging. The company seeks to address diseases associated with aging by identifying therapeutic targets linked to human longevity and translating those discoveries into drug candidates.

BioAge uses large human data sets, computational biology, and machine-learning tools to study the molecular factors that influence healthy aging and age-related disease. Its research has produced a pipeline of investigational therapies, including azelaprag (BGE-105), an apelin receptor agonist being evaluated for potential applications involving metabolic health, body composition, and physical function.

Founded in 2015, BioAge is headquartered in Richmond, California, and conducts research and clinical development activities through collaborations and studies involving patients and research sites in multiple regions.